关注
Angela M Minassian
Angela M Minassian
在 bioch.ox.ac.uk 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
54172021
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
28122020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...
The Lancet 396 (10267), 1979-1993, 2020
17002020
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
13562021
Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne, F Burns, ...
New England Journal of Medicine 385 (13), 1172-1183, 2021
9902021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
7442021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
7442021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre …
APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ...
The Lancet 398 (10318), 2258-2276, 2021
6902021
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ...
Nature medicine 27 (2), 270-278, 2021
6092021
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ...
Nature medicine 27 (2), 279-288, 2021
3422021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ...
The Lancet 398 (10304), 981-990, 2021
2732021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ...
The lancet HIV 8 (8), e474-e485, 2021
2242021
Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected Individuals
CR Sander, AA Pathan, NER Beveridge, I Poulton, A Minassian, N Alder, ...
American journal of respiratory and critical care medicine 179 (8), 724-733, 2009
1512009
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a …
APS Munro, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, ...
The Lancet Infectious Diseases 22 (8), 1131-1141, 2022
1472022
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions
RO Payne, SE Silk, SC Elias, K Miura, A Diouf, F Galaway, H de Graaf, ...
JCI insight 2 (21), 2017
1432017
Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
Lancet 397 (10269), 99-111, 2021
1402021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer …
S Toback, E Galiza, C Cosgrove, J Galloway, AL Goodman, PA Swift, ...
The Lancet Respiratory Medicine 10 (2), 167-179, 2022
1392022
Use of an automated blood culture system (BD BACTEC™) for diagnosis of prosthetic joint infections: easy and fast
AM Minassian, R Newnham, E Kalimeris, P Bejon, BL Atkins, ...
BMC infectious diseases 14 (1), 1-7, 2014
1222014
A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
AM Minassian, I Satti, ID Poulton, J Meyer, AVS Hill, H McShane
Journal of Infectious Diseases 205 (7), 1035-1042, 2012
1172012
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
AM Minassian, SE Silk, JR Barrett, CM Nielsen, K Miura, A Diouf, C Loos, ...
Med 2 (6), 701-719. e19, 2021
1162021
系统目前无法执行此操作,请稍后再试。
文章 1–20